<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408395</url>
  </required_header>
  <id_info>
    <org_study_id>V70P2</org_study_id>
    <secondary_id>2006-003181-34</secondary_id>
    <nct_id>NCT00408395</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children</brief_title>
  <official_title>A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine Versus Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a study of the safety and immunogenicity of three commercially available influenza
      vaccines in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical
      Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of
      a commercially available influenza vaccine versus Two 0.25 mL Intramuscular Doses of a
      commercially available influenza vaccine in Healthy Children
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the immunogenicity of the 2 vaccines in terms of post-immunization geometric mean titers (GMTs), as measured by the hemagglutination inhibition (HI) test</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunogenicity of the 2 vaccines in terms of seroprotection, and seroconversion or significant increase, as measured by HI test</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of the 2 vaccines administered 4 weeks apart</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1: Trivalent Seasonal Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Adjuvanted Trivalent Seasonal Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>Seasonal Influenza Vaccine</description>
    <arm_group_label>1: Trivalent Seasonal Influenza Vaccine</arm_group_label>
    <arm_group_label>2: Adjuvanted Trivalent Seasonal Influenza Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 months to &lt; 36 months of age

        Exclusion Criteria:

          -  Any severe acute respiratory disease and infections requiring systemic antibiotic or
             antiviral therapy ongoing or resolved within 30 days prior to study start (chronic
             antibiotic therapy for urinary tract prophylaxis is acceptable)

          -  Other serious diseases such as: cancer, autoimmune disease (including rheumatoid
             arthritis), diabetes mellitus, chronic pulmonary disease, acute or progressive hepatic
             or renal disease, or surgery planned during the study period.

          -  Known or suspected impairment/alteration of immune function

          -  History of hypersensitivity to any component of the study vaccine, egg products or
             other vaccine component, or impairment/alteration of immune function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines (formerly Chiron Vaccines)</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Tampere Medical School</name>
      <address>
        <city>Tampere</city>
        <zip>33014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <results_reference>
    <citation>Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.</citation>
    <PMID>19561422</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2006</study_first_submitted>
  <study_first_submitted_qc>December 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2006</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>children</keyword>
  <keyword>vaccine</keyword>
  <keyword>influenza disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

